Biogen Idec buys analgesic developer Convergence for $200m+
This article was originally published in Scrip
Biogen Idec has agreed to pay $200m up front and up to $475m in milestones to acquire the UK developer of drugs for neuropathic pain Convergence Pharmaceuticals. The target company's most promising pipeline drug is CNV1014802, which has yielded positive Phase II results for trigeminal neuralgia (TGN), an orphan condition characterized by excruciating face pain.
You may also be interested in...
The deal for an oral orexin-1 receptor antagonist which aims to treat addiction by targeting the craving process validates C4XD's strategy of out-licensing preclinical programs. CEO Clive Dix told Scrip more agreements will follow as the firm "is not a one-trick pony."
New cash will fund further clinical testing of NeRRe's two neurokinin receptor antagonists for cough and hot flashes.
A year after COVID-19 first turned the world upside down, executives across the biopharma industry consider what 2021 holds in store. The impact of the pandemic will have profound and long-lasting implications for a sector that has been at the heart of responding to the global health challenge.